eCTD Publishing, Validation & Gateways
eCTD
Publishing
The science wins approval. The submission has to arrive first.
The science wins approval. The submission has to arrive first.
Regulatory operations is the discipline that turns finished science into a submission an agency will accept. It is not the strategy and it is not the writing; it is the exacting, unforgiving work of assembling thousands of documents into a compliant, navigable, machine-readable dossier and transmitting it through the right gateway on the day it is due. Done well, nobody notices. Done poorly, a technical rejection turns a finished dossier into a missed date.
Sequences, hyperlinks, and validation that keep the dossier current across its whole life.
Publishing is a pipeline, and every stage is a place a filing can fail. We run the whole path, so the error is caught in-house and not at the gateway with the deadline standing.
A perfect dossier still has to arrive, through the right gateway, on the day it is due.
Source documents meet the technical rules: PDF versions, bookmarks, hyperlinks, and naming. Errors here propagate into every sequence.
Each file takes its place in the CTD structure, granularity applied consistently, and the whole compiled into a valid eCTD sequence.
Checked against current regional criteria plus an independent QC, because a dossier can pass every technical check and still be wrong.
Each authority's gateway, accounts, and acknowledgement cycle managed end to end, with certificates in place well ahead of time.
Every amendment and variation is a new sequence that must reconcile with the ones before, kept coherent for years.
eCTD is a global standard, but each authority runs its own gateway, its own validation criteria, and its own account and acknowledgement mechanics. We publish and transmit to the agencies that matter to your program, and to the long tail of markets behind them.
IND, NDA, ANDA, BLA, and DMF via the Electronic Submissions Gateway (ESG).
MAA, variations, ASMF, and CTA via the eSubmission Gateway and CESP.
National submissions through MHRA Submissions and CESP.
NDS, SNDS, ANDS, and CTA via the Common Electronic Submissions Gateway.
eCTD submissions, prepared ahead of the v4.0 mandate for new applications.
TGA eCTD and NeeS, plus the reliance markets behind your major filings.
Transmission is the easy part when the account, certificate, and acknowledgement mechanics are already handled.
eCTD v4.0 is not a cosmetic update. Built on the HL7 RPS standard, it changes how documents are reused and how lifecycle is expressed, and agencies are moving to it on staggered, firm timelines. We plan the transition so you keep filing without interruption while others discover the change mid-submission.
A submission bounced by validation, a technical rejection notice, a dossier whose lifecycle has drifted, a vendor gone silent days before filing: these arrive without warning and rarely with time to spare. We step into submissions in trouble, diagnose why the sequence failed, and fix it against the clock.
Publishing is judged on whether the sequence is accepted, on time, the first time. Your leads are senior submission and publishing practitioners who have compiled, validated, and transmitted dossiers to the FDA, EMA, and the authorities beyond, and rescued the ones that bounced.
FDA ESG, EMA and CESP, MHRA, Health Canada, PMDA, and the long tail, with the account and certificate mechanics each one demands.
We catch the error in-house, against current regional criteria, not at the gateway with the deadline standing.
Every sequence reconciled to the ones before it, so the dossier's history never quietly breaks.
We plan the eCTD v4.0 transition ahead of the mandates, so the format change never becomes a missed date.
A submission is the last step of a much larger program. These are the services it most directly carries.
The broader operating function, RIM, and reliability that publishing sits inside.
Explore Operations →Module 3, authored and reconciled so the quality section compiles cleanly into the sequence.
Explore CMC →The end-to-end filing strategy across FDA, EU, and global agencies that publishing turns into a compliant sequence.
Explore Submissions →Tell us what's ahead: a first eCTD, a marketing application, a global lifecycle to maintain, or a sequence that just failed validation. We'll match you with a senior regulatory operations lead and respond within one business day. All inquiries are strictly confidential.
